Stock GRF.P GRIFOLS, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Grifols, S.A. BME

Equities

GRF.P

ES0171996095

Pharmaceuticals

Market Closed - BME
Other stock markets
 16:35:24 27/06/2024 BST 		5-day change 1st Jan Change
5.62 EUR -13.14% Intraday chart for Grifols, S.A. -12.67% -46.73%
06-27 European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
06-27 Grifols Shares Fall Premarket Following Downgrade by Moody's MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,760 14,161 9,783 6,557 9,231 4,809 - -
Enterprise Value (EV) 1 25,225 20,597 16,478 15,716 18,568 14,092 13,547 13,041
P/E ratio 34.5 x 26.5 x 62.5 x 34.7 x 172 x 11.8 x 7.48 x 6.16 x
Yield 1.15% 0.71% 2.13% - - 0.57% 2.89% 5.8%
Capitalization / Revenue 3.68 x 2.65 x 1.98 x 1.08 x 1.4 x 0.68 x 0.63 x 0.59 x
EV / Revenue 4.95 x 3.86 x 3.34 x 2.59 x 2.82 x 1.99 x 1.78 x 1.61 x
EV / EBITDA 17.9 x 13.9 x 17.1 x 12.9 x 12.8 x 7.81 x 6.42 x 5.7 x
EV / FCF 161 x 25.7 x 52.1 x -56.7 x -213 x 15.9 x 18.3 x 13.7 x
FCF Yield 0.62% 3.9% 1.92% -1.76% -0.47% 6.3% 5.46% 7.29%
Price to Book 4.46 x 1.99 x 1.89 x 1.19 x 1.79 x 0.82 x 0.74 x 0.67 x
Nbr of stocks (in thousands) 684,135 684,540 682,484 678,911 678,665 679,092 - -
Reference price 2 31.43 23.88 16.88 10.77 15.46 7.970 7.970 7.970
Announcement Date 27/02/20 26/02/21 28/02/22 28/02/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,099 5,340 4,933 6,064 6,592 7,098 7,606 8,125
EBITDA 1 1,407 1,479 961.5 1,221 1,455 1,805 2,111 2,287
EBIT 1 1,131 996.1 595.1 805.7 1,023 1,240 1,567 1,700
Operating Margin 22.19% 18.65% 12.06% 13.29% 15.52% 17.46% 20.6% 20.93%
Earnings before Tax (EBT) 1 817.1 878.6 350.5 361.3 224 823.1 1,147 1,231
Net income 1 625.1 618.5 182.8 208.3 59.32 432.6 687.3 824.7
Net margin 12.26% 11.58% 3.71% 3.43% 0.9% 6.09% 9.04% 10.15%
EPS 2 0.9100 0.9000 0.2700 0.3100 0.0900 0.6728 1.066 1.295
Free Cash Flow 1 156.6 802.2 316.1 -277.4 -87.14 887.8 739.6 950.1
FCF margin 3.07% 15.02% 6.41% -4.57% -1.32% 12.51% 9.72% 11.69%
FCF Conversion (EBITDA) 11.13% 54.24% 32.87% - - 49.2% 35.04% 41.55%
FCF Conversion (Net income) 25.05% 129.7% 172.91% - - 205.24% 107.61% 115.21%
Dividend per Share 2 0.3600 0.1700 0.3600 - - 0.0455 0.2301 0.4626
Announcement Date 27/02/20 26/02/21 28/02/22 28/02/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2,677 2,537 1,198 1,198 2,396 1,405 1,543 2,810 1,541 1,713 3,254 1,561 1,663 3,225 1,597 1,770 1,626 1,770 1,754 1,877
EBITDA 1 731.4 634.5 - - 327 248.2 - 618.3 308 294 602.7 298.8 360.7 659.5 373.6 426.3 350.4 432.1 437.3 488.9
EBIT 1 421.7 463.6 - - 131.5 - - 427.3 173.4 176.9 378.3 175.7 253.6 - 264.4 329.3 203.8 324.1 339.5 380.2
Operating Margin 15.75% 18.27% - - 5.49% - - 15.21% 11.25% 10.33% 11.63% 11.25% 15.25% - 16.55% 18.61% 12.54% 18.31% 19.35% 20.26%
Earnings before Tax (EBT) 1 - 378.2 - - -27.78 - - 227.9 66.69 46.88 133.4 -84.17 103.2 19.05 99.59 105.4 47.06 86.75 116.8 187.5
Net income 1 218.2 266.8 - - -84.01 - - 143.6 45 20.07 64.63 -108.3 52.04 -56.22 59.54 55.99 21.42 82.13 100.6 126.2
Net margin 8.15% 10.52% - - -3.51% - - 5.11% 2.92% 1.17% 1.99% -6.93% 3.13% -1.74% 3.73% 3.16% 1.32% 4.64% 5.74% 6.73%
EPS 2 - 0.3900 -0.0600 - -0.1200 - - 0.2100 - - 0.1000 - 0.0800 - - - 0.0665 0.1729 0.1906 0.1766
Dividend per Share - - - - - - - - - - - - - - - - - - - -
Announcement Date 30/07/20 29/07/21 28/02/22 28/02/22 28/02/22 28/07/22 28/07/22 28/07/22 08/11/22 28/02/23 28/02/23 09/05/23 27/07/23 27/07/23 02/11/23 28/02/24 14/05/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,465 6,436 6,695 9,158 9,337 9,283 8,738 8,232
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4.595 x 4.352 x 6.963 x 7.501 x 6.419 x 5.144 x 4.14 x 3.6 x
Free Cash Flow 1 157 802 316 -277 -87.1 888 740 950
ROE (net income / shareholders' equity) 15.9% 12.5% 3.26% 3.57% 3.72% 7.32% 11% 11.9%
ROA (Net income/ Total Assets) 5.13% 4.01% 1.06% 1.02% 1.04% 2.06% 3.21% 3.25%
Assets 1 12,193 15,409 17,254 20,384 5,701 21,048 21,433 25,378
Book Value Per Share 2 7.050 12.00 8.950 9.040 8.640 9.720 10.70 11.90
Cash Flow per Share 2 0.8300 1.620 0.8800 -0.0200 0.3100 1.260 1.600 2.070
Capex 1 412 308 281 266 295 536 372 370
Capex / Sales 8.09% 5.77% 5.69% 4.39% 4.48% 7.56% 4.89% 4.56%
Announcement Date 27/02/20 26/02/21 28/02/22 28/02/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Grifols, S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
7.97 EUR
Average target price
17.41 EUR
Spread / Average Target
+118.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+2.97% 94.74B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.68% 37.28B
BIOGEN INC. Stock Biogen Inc.
-11.61% 32.68B
UCB Stock UCB
+74.21% 27.72B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.40% 16.19B
INCYTE CORPORATION Stock Incyte Corporation
-2.29% 13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.21% 11.58B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+188.83% 10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-53.94% 9.54B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. GRF.P Stock
  5. Financials Grifols, S.A.